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Abstract
Background: Purification of recombinant membrane receptors is commonly achieved by use of an affinity tag followed by
an additional chromatography step if required. This second step may exploit specific receptor properties such as ligand
binding. However, the effects of multiple purification steps on protein yield and integrity are often poorly documented. We
have previously reported a robust two-step purification procedure for the recombinant rat neurotensin receptor NTS1 to
give milligram quantities of functional receptor protein. First, histidine-tagged receptors are enriched by immobilized metal
affinity chromatography using Ni-NTA resin. Second, remaining contaminants in the Ni-NTA column eluate are removed by
use of a subsequent neurotensin column yielding pure NTS1. Whilst the neurotensin column eluate contained functional
receptor protein, we observed in the neurotensin column flow-through misfolded NTS1.
Methods and Findings: To investigate the origin of the misfolded receptors, we estimated the amount of functional and
misfolded NTS1 at each purification step by radio-ligand binding, densitometry of Coomassie stained SDS-gels, and protein
content determination. First, we observed that correctly folded NTS1 suffers damage by exposure to detergent and various
buffer compositions as seen by the loss of [
3H]neurotensin binding over time. Second, exposure to the neurotensin affinity
resin generated additional misfolded receptor protein.
Conclusion: Our data point towards two ways by which misfolded NTS1 may be generated: Damage by exposure to buffer
components and by close contact of the receptor to the neurotensin affinity resin. Because NTS1 in detergent solution is
stabilized by neurotensin, we speculate that the occurrence of aggregated receptor after contact with the neurotensin resin
is the consequence of perturbations in the detergent belt surrounding the NTS1 transmembrane core. Both effects reduce
the yield of functional receptor protein.
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Introduction
Structural and functional work on G-protein-coupled receptors
[1,2] such as the rat neurotensin receptor NTS1 [3] requires a
reliable source of high-quality material. NTS1 occurs naturally at
low levels; recombinant expression [4] and efficient purification
methods are therefore needed to obtain pure NTS1. We
established a bacterial expression system for the production of
functional, membrane-inserted NTS1 [5] whereby the Escherichia
coli maltose-binding protein (MBP) is fused to the receptor N-
terminus. The E. coli thioredoxin at the receptor C-terminus was
found to improve expression levels [6] and a C-terminal deca-
histidine tag allowed the efficient capture of the NTS1 fusion
protein by immobilized metal affinity chromatography (IMAC)
[7]. We developed an automated procedure for the purification of
fully functional NTS1 in detergent solution at the 3-milligram or
10-milligram level [8]. IMAC is the first purification step to enrich
the NTS1 fusion protein. The second step makes use of a
neurotensin (NT) column to remove contaminants remaining from
the first purification step [8]. Receptors eluted from the NT
column are pure and fully functional as assessed by radio-ligand
binding and G-protein coupling experiments [8,9].
As notedabove,thecontaminantspresentin the Ni-NTA column
eluate can be removed by the subsequent NT column step.
However, we also observed a considerable amount of NTS1 in the
NT column flow-through. These receptors are initially detergent-
soluble, do not bind ligand [8], and aggregate over time. Because
the misfolded NTS1 species is unsuitable for biochemical work but
constitutes a substantial fraction of the total amount of NTS1, we
investigated the origin of the misfolded receptors to potentially take
measures against NTS1 aggregation and to maximize the yield of
functional NTS1. We detected some misfolded NTS1 in the Ni-
NTA column eluate which could have arisen during biosynthesis in
E. coli cells or by damage of intact receptors after solubilization with
detergents. However, exposure of functional NTS1 in the Ni-NTA
column eluate to the NT affinity resin generated additional
misfolded receptor protein. Because NT stabilizes NTS1 in
detergent solution, aggregation of NTS1 is likely caused by close
contact of the receptor with the NT column matrix, thus reducing
the overall yield of purified functional NTS1.
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Materials
The tritiated agonist [
3H]neurotensin ([
3H]NT: [3,11-tyrosyl-
3,5-
3H(N)]-pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-
Ile-Leu) was purchased from Perkin Elmer. Unlabeled neurotensin
(NT) was purchased from Sigma. The detergents n-dodecyl-b-D-
maltopyranoside (DDM) and 3-[(3-cholamidopyropyl)dimethylam-
monio]-1-propanesulfonate (CHAPS), and cholesteryl hemisuccinate
Tris salt (CHS) were obtained from Anatrace.
Expression of NTS1 in Escherichia coli
The NTS1 fusion protein MBP-T43NTR-TrxA-H10 (NTS1-
624) consists of the E. coli maltose-binding protein (MBP, Lys1 to
Thr366), followed by Gly-Ser, the N-terminally truncated rat
neurotensin type I receptor NTS1 (T43NTR, Thr43 to Tyr424),
three Ala residues, the E. coli thioredoxin (TrxA, Ser2 to Ala109),
Gly-Thr and a decahistidine tag (H10). We refer here to NTS1-
624 as NTS1. NTS1 was produced in E. coli as described [7,8].
Batch purification of NTS1 by immobilized metal affinity
chromatography
All steps were carried out at 4uC or on ice. Solubilization of
NTS1 was done as previously described (for details see reference
[8]). Briefly, 10 gram of E. coli cells were processed in a final
volume of 50 ml (final buffer composition: 50 mM Tris-HCl
pH 7.4, 30% (v/v) glycerol, 200 mM NaCl, 1% (w/v) DDM,
0.6% (w/v) CHAPS, 0.12% (w/v) CHS, protease inhibitors:
70 mg/ml phenylmethylsulfonyl-fluoride (PMSF), 1 mg/ml leupep-
tin, 1.4 mg/ml pepstatin A, 5 mg/ml DNaseI and 5 mM MgCl2).
After sonication (8 sec/gram of cells), unbroken cells and debris
was removed by ultracentrifugation. Imidazole was then added to
the supernatant (SN) to a final concentration of 50 mM. Binding
of receptors to Ni-NTA Superflow resin (Qiagen, 5 ml settled
resin) was done overnight in batch. The Ni-NTA column flow-
through (NiFT) was collected for analysis. The Ni-NTA resin was
washed four times with 20 ml of buffer NiA (50 mM Tris-HCl
pH 7.4, 30% glycerol, 200 mM NaCl, 50 mM imidazole, 0.1%
DDM, 0.5% CHAPS, 0.1% CHS). Elution was done with buffer
NiB (NiA buffer with 200 mM imidazole).
Purification of NTS1 by neurotensin affinity
chromatography
The second purification step of the NTS1 fusion protein was
performed using an A ¨kta Purifier system (GE Healthcare). The Ni-
NTA column eluate (NiE) was diluted 2.85-fold with buffer NT0
(50 mM Tris-HCl pH 7.4, 30% glycerol, 0.1% DDM, 0.5%
CHAPS, 0.1% CHS) to reduce the NaCl and imidazole
concentrations to 70 mM and hence allow binding of NTS1 to
the neurotensin column (NT column) [10]. The diluted NiE was
loaded onto a NT column (4 ml resin packed into a XK16/60
column) [6] at a flow rate of 0.4 ml/min. After loading was
completed, the NT column was washed with NT70 buffer (NT0
buffer with 70 mM NaCl; 20 column volumes). NTS1 was eluted
from the NT column with buffer NT1K (NT0 buffer with 1 M
NaCl).
Radio-ligand binding assays
Agonist binding to the detergent-solubilized receptor fusion
protein was analyzed with [
3H]neurotensin ([
3H]NT) (PerkinEl-
mer) in assay buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA,
0.1% BSA, 0.004% bacitracin) containing detergent (0.1% DDM,
0.2% CHAPS, 0.04% CHS) for 1 hour on ice. The reaction
volume was 150 ml. Non-specific [
3H]NT binding was determined
in the presence of 10 mM unlabeled NT. Separation of the
receptor-ligand complex from free ligand (100 ml) was achieved by
centrifugation-assisted gel filtration using Bio-Spin 30 Tris
columns (Bio-Rad) according to the manufacturer’s instructions.
Samples were analyzed by liquid scintillation counting [8].
The apparent affinity of NT for solubilized NTS1 is reduced in
the presence of Na
+-ions [10,11] and imidazole [10]. Therefore,
NTS1 was diluted with dilution buffer (50 mM Tris-HCl pH 7.4,
1 mM EDTA, 0.1% DDM, 0.2% CHAPS, 0.04% CHS) prior to
binding assays to minimize the carry-over of detergents and buffer
components from the respective purification steps, and hence to
lessen their effects on [
3H]NT binding.
For saturation binding analyses, the [
3H]NT concentration was
varied from 0.3–10 nM. Data were analyzed by nonlinear
regression using Prism software version 4 (GraphPad). A one-site
binding equation was used to determine the values for maximal
binding (Bmax) and the equilibrium dissociation constants (Kd) with
n denoting the number of independent experiments (SN:
Kd=1.09 nM60.05, n=6; NiE: Kd=0.41 nM60.03, n=6;
NTE: Kd=0.46 nM60.05, n=4). Single-point ligand binding
experiments were conducted at a [
3H]NT concentration of 2 nM,
and the amount of specifically bound [
3H]NT was then corrected
for fractional occupancy using the respective Kd value [12].
Stability of NTS1 during purification
The stability of NTS1 in the SN, NiE and diluted NiE fractions
at 4uC was assessed by measuring [
3H]NT binding to receptors
over time. Prior to each ligand binding assay, NTS1 was diluted
into receptor dilution buffer. Agonist binding measurements were
conducted at a [
3H]NT concentration of 2 nM. Half-lives were
calculated by nonlinear regression using the one phase exponential
decay function (Prism software) (Table 1).
To investigate the effect of NT on the stability of NTS1 in the
diluted NiE fraction, we used a modified stability test. Receptors
were diluted to a concentration of 9 nM into NT70 buffer
containing [
3H]NT at a final concentration of 10 nM. At various
time points, 100 ml of the reaction mixture was processed over Bio-
Spin 30 Tris columns. Non-specific binding was determined in the
presence of 10 mM unlabeled NT. For comparison, we assessed
the stability of NTS1 in diluted NiE in the absence of NT. For this,
NTS1 was diluted into NT70 buffer to 10 nM. At the required
time points, [
3H]NT was added to a final concentration of 10 nM
(reducing the receptor concentration to 9 nM). After one hour
incubation on ice, 100 ml of the reaction mixture was processed
over Bio-Spin 30 Tris columns.
Table 1. Stability of NTS1 in the absence of agonist.
Sample tK (hrs) ± SE % left after xx hrs
SN (n=4) 124613 91%63, 24 hrs
NiE (n=7) 138689 7 % 61, 6 hrs
diluted NiE (n=6) 45639 1 % 61, 6 hrs
[
3H]NT binding to the NTS1 fusion protein was recorded over time and half-lives
were calculated. The amount of functional NTS1 remaining after 6 hrs (NiE and
diluted NiE) and after 24 hrs (SN) was estimated from one phase exponential
decay fits. Abbreviations: SN, supernatant after ultracentrifugation; NiE, Ni-NTA
column eluate.
doi:10.1371/journal.pone.0012579.t001
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The protein content was measured according to the method of
Schaffner and Weissmann [13] with bovine serum albumin as the
standard.
SDS-PAGE and Western blot analysis of E. coli cells and
SN samples
E. coli cells were collected by centrifugation. The cell pellet was
suspended in H2O and the volume was immediately determined.
SDS was then added to a final concentration of 2% followed by
incubation for 1 hour at ambient temperature. 46LDS reducing
sample buffer (Invitrogen) was then added to give 16 sample
buffer concentrations. The final volume was ,20% of the original
cell culture volume. After centrifugation at 16,0006g for 30 min,
the supernatant was used for gel electrophoresis.
The protein supernatant samples after detergent solubilization
and ultracentrifugation (SN samples, see section ‘‘Batch purifica-
tion of NTS1 by immobilized metal affinity chromatography’’)
were adjusted with 46 LDS reducing sample buffer to give 16
sample buffer concentrations and further diluted if required.
Proteins were separated by SDS-PAGE on NuPAGE 4–12%
Bis-Tris gels in MES buffer and transferred to ImmobilonP
polyvinylidene fluoride membranes (Millipore) in transfer buffer
(25 mM Tris base pH 8.3, 150 mM glycine, 0.05% SDS, 5%
methanol) using the Hoefer semi-dry blotter (100 mA, 40 min).
After blocking in phosphate buffered saline (PBS) supplemented
with 0.05% Tween-20 and 3% BSA, the ImmobilonP membranes
were incubated with INDIA HisProbe-HRP (1:5000, Pierce) for
45 min. The membranes were then washed twice for 5 min with
PBS, 0.05% Tween-20, and once for 5 min with PBS. The
subsequent incubation with SuperSignal West Pico chemilumi-
nescent substrate (Pierce) was done according to the manufactur-
er’s instructions. Membranes were exposed to x-ray film (Kodak
Biomax XAR) for defined time intervals.
For ImageJ quantification by Western blot of NTS1 in E. coli
cells and the SN samples, 10–90 ng of purified reference NTS1
fusion protein was loaded per lane.
SDS-PAGE of NiE, NTFT and NTE
The NiE, NTFT and NTE samples were precipitated prior to
gel electrophoresis by addition of methanol and chloroform, and
air dried. Proteins were then dissolved for 1 hour in a 2% SDS
solution at 0.3–1.3 mg/ml. Finally, 46 LDS reducing sample
buffer (Invitrogen) was added to give 16 sample buffer
concentrations. Proteins were separated on NuPAGE 4–12%
Bis-Tris gels in MES buffer and stained with SimplyBlue SafeStain
(Invitrogen). The Perfect Protein Marker (15–150 kDa) used as
standard was purchased from Novagen.
For ImageJ quantification of NTS1 in the NiE, NTFT and
NTE fractions, a range of purified reference NTS1 fusion protein
(0.5–4 mg per lane) was included on Coomassie-stained gels.
ImageJ analysis of films and Coomassie-stained gels
Developed films and Coomassie-stained gels were scanned using
a HP ScanJet 8300 scanner with the resolution set to 600 pixels/
inch. The scans were saved as tif files and imported into the
ImageJ software package (Rasband, ImageJ, U.S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.
nih.gov/ij/, 1997–2008) [14]. The intensities of the protein bands
were plotted and integrated to give area values.
The ng/mg-amounts of NTS1 in cell samples, SN, NiE, NTFT
and NTE were then calculated as follows.
NTS1 in E. coli cells and SN (Western blot, film): A standard
curve was constructed from purified reference NTS1 fusion
protein by relating the ImageJ-derived areas of the reference
protein to the known ng-amounts loaded per lane. The ng-amount
of the target NTS1 was calculated by comparing the ImageJ-
derived area to the standard curve by linear regression.
NTS1 in the NiE, NTFT and NTE fractions: A standard curve
was constructed from purified reference NTS1 fusion protein by
relating the ImageJ-derived areas of the reference protein to the
known mg-amounts loaded per lane. The mg-amount of the target
NTS1 was calculated by comparing the ImageJ-derived area to the
standard curve by linear regression. This approach assumes that
Amido Black binds equally well to bovine serum albumin, used as
standard for determination of the protein content, and to the
purified reference NTS1 fusion protein. Coomassie Blue is
expected to bind equally well to the purified reference NTS1
fusion protein and to the target NTS1. The comparison of the
ImageJ-calculated mg-amounts of NTS1 with amounts determined
by [
3H]NT saturation binding experiments allowed to estimate the
percentage of functional NTS1 in the NiE, NTFT and NTE.
Data compilation in Table 2
The columns and rows of Table 2 are numbered and a
particular cell within Table 2 is referred to as [column/row].
Column A lists the amount of functional NTS1 in the NiE, NTFT
and NTE fractions determined by [
3H]NT binding experiments
(see Tables 3 and 4) and stability measurements (Table 1). For
NiE, the amount of functional NTS1 was corrected for the loss of
functional receptors during the 6 hour time interval needed for
completion of the NT column step (Table 1). This decrease of the
amount of functional NTS1 in the NiE fraction is indicated by a
left pointing arrow in [A/1]. The corresponding amount of
misfolded NTS1 is listed in [A/2]. The analysis of [
3H]NT
binding to NTS1 in the NTFT and NTE fractions was done
12 hours after these fractions became available. No decrease of
ligand binding was observed for NTS1 in the NTE over a time
period of 12 hours. Column B lists information from ImageJ
analysis of Coomassie-stained gels (Table 4), [
3H]NT binding
assays (Tables 3 and 4) and protein content determination by the
Amido Black method (Table 3). [B/3] gives the total amount of
NTS1 (Table 4). Subtracting from [B/3] the amount of functional
NTS1 ([B/1], Tables 3 and 4) gives the amount of misfolded
NTS1 [B/2]. For NiE, the amount of functional NTS1 [B/1] was
corrected for the loss of functional receptors during the 6 hour
time interval needed for completion of the NT column step (left
pointing arrow in [B/1], see Table 1); the respective amount of
misfolded NTS1 is listed in [B/2]. The amount of contaminating
protein [B/4] was calculated by subtracting the total amount of
NTS1 [B/3] from the entire protein content of the respective
fraction determined by the Amido Black method [B/5]. Column
C uses the specific [
3H]NT binding values, calculated from
[
3H]NT binding and from the protein content by the Amido Black
method (Table 3), to determine the amount of functional NTS1 in
the NiE and NTE fractions. For this, the respective specific
binding values (Table 3) are compared to the theoretical value of
10363 pmol/mg (see Table 3) to give the percentage functional
NTS1 per total protein. The amount of functional NTS1 [C/1]
was then calculated from the total protein content of the respective
fraction (Table 3) and the percentage of functional NTS1. For
NiE, the amount of functional NTS1 [C/1] was corrected for the
loss of functional receptors during the 6 hour time interval needed
for completion of the NT column step (left pointing arrow in [C/
1], Table 1); the respective amount of misfolded NTS1 is listed in
[C/2].
Stability of NTS1
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12579Table 3. Purification of NTS1.
Volume (ml)
Functional
receptor (pmoles) Protein (mg)
Specific binding
(pmol/mg)
Recovery (% by
[
3H]NT binding)
Recovery (% by
Amido Black assay)
SN (n=6) 44.660.2 57706352 394618 13.060.4 100 100
NiFT (n=6) 50.260.2 761660 ND ND 1361N D
NiE (n=4) 14.260.3 39266178 1.0060.10 37246354 73630 . 3 60.03
NiE loaded 13.460.4 36786165 0.9260.06 100 100
NTFT (n=3) 41.860.9 7064 0.5360.03 260.1 5962
NTE (n=4) 3.560.0 1286652 0.1360.01 99116826 3560.5 1460.5
Data are given 6 SE. The volume of the NTFT is larger than that of the NiE because of the dilution applied to reduce the NaCl and imidazole concentrations. Recovery
data of the NiFT and NiE relate to SN, whereas recovery data of the NTFT and NTE relate to the NiE loaded onto the NT-column. A theoretical value for specific binding of
10363 pmol/mg is calculated for NTS1 (molecular mass of 96.5 kDa) assuming one ligand binding site per receptor molecule. Abbreviations: SN, supernatant after
ultracentrifugation; NiFT, flow-through of Ni-NTA column; NiE, Ni-NTA column eluate; NTFT, flow-through of NT column; NTE, NT column eluate; ND, not determined.
doi:10.1371/journal.pone.0012579.t003
Table 2. Functional and misfolded NTS1 during purification.
By Ligand
binding
By Image J
analysis of gels
By Specific
binding
Average across row using
independent parameters
Percentage relative to
protein species in NiE (%)
AB CD
NiE 80%
4 fct. 36%
3
1 Functional NTS1 0.323
5r0.355
1 0.323
5r0.355
1,6 0.301
5r0.331
3 0.312 100
2 Misfolded NTS1 0.032
5 0.032
5+0.088
6 0.030
5 0.119 100
3 Total NTS1 NA 0.443
2 NA 0.443 100
4 Contaminants NA 0.477
7 NA 0.477 100
5 Total protein NA 0.920
8 0.920
8 0.920 100
NTFT 4%
4 fct
1 Functional NTS1 0.007
1 0.007
1 NA 0.007 2
2 Misfolded NTS1 NA 0.164
6 NA 0.164 138
3 Total NTS1 NA 0.171
2 NA 0.171 39
4 Contaminants NA 0.359
7 NA 0.359 75
5 Total protein NA 0.530
8 0.530
8 0.530 58
NTE 101%
4 fct 96%
3
1 Functional NTS1 0.124
1 0.124
1 0.124
3 0.124 40
2 Misfolded NTS1 NA NA 0.006 0.006 5
3 Total NTS1 0.124 0.123
2 0.130
8 0.126 28
4 Contaminants NA 0.007
7 NA 0.007 2
5 Total Protein 0.124 0.130
8 0.130
8 0.127 14
Three different ways (columns A–C) were used to estimate the amounts of functional NTS1, misfolded NTS1 and contaminants in the NiE, NTFT and NTE fractions. All
values in columns A–D are given in mg quantities. Abbreviations: NiE, Ni-NTA column eluate; NTFT, flow-through of NT column; NTE, NT column eluate; NA, not
applicable.
1The amount of functional NTS1 in the NiE, NTFT and NTE fractions was determined by [
3H]NT binding (see Tables 3 and 4). For example, the NiE contained 3678 pmoles
or 0.355 mg functional NTS1.
2The total amount of NTS1 protein in the NiE, NTFT and NTE fractions was determined by ImageJ analysis of Coomassie-stained gels (Table 4).
3The amount of functional NTS1 in the NiE and NTE fractions was derived from the respective specific [
3H]NT binding values (in pmol/mg, Table 3) compared to the
theoretical value of 10363 pmol/mg. For example, the NiE fraction has a specific binding value of 3724 pmol/mg and hence 36% (3724/10363) of the total protein in
NiE (0.92 mg) is functional NTS1 (0.331 mg).
4The amount of functional NTS1 was estimated from data in Table 4.
5The diluted NiE is 91% functional after 6 hrs (Table 1). This decrease of the amount of functional NTS1 is indicated by a left pointing arrow. The corresponding amount
of misfolded NTS1 is listed.
6The amount of functional and misfolded NTS1 was calculated from the total NTS1 amount in the respective fractions considering the proportion of functional receptors
(Table 4). For example, the NiE contained 0.443 mg total NTS1 which is 80% functional
4 i.e. 0.355 mg functional NTS1 and 0.088 mg misfolded NTS1.
7The amount of contaminants was calculated by subtracting the total NTS1 amount from the total protein content of a given fraction (Table 4).
8The total protein content of the NiE, NTFT and NTE fractions was determined by the Amido Black method.
doi:10.1371/journal.pone.0012579.t002
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The progress of purification of NTS1 by IMAC followed by a
neurotensin (NT) column is shown in Figure 1 and in Table 3. The
Ni-NTA column eluate (NiE) contained two major proteins, NTS1
and a 67 kDa protein identified as glucosamine-fructose-6-
phosphate aminotransferase by mass spectrometry and N-terminal
sequence analysis (data not shown). The subsequent NT column
step efficiently removed the contaminants; however, the NT
column flow-through (NTFT) also contained a considerable
amount of NTS1 which no longer interacted with NT. NTS1 in
the NTFT severely aggregated over time (data not shown)
indicating that this receptor species was misfolded. Because
correctly folded receptors bind radio-ligand, but misfolded
receptors do not, one can approximate at the various purification
steps the percentage of functional receptors by comparing [
3H]NT
binding data with estimates of the total amount of NTS1
(functional and misfolded). This approach allowed identifying
the source of misfolded receptors found in the NTFT.
If incorrectly folded receptors arise in E. coli during NTS1
biosynthesis, detergent extraction would result in a mixture of
misfolded and correctly folded receptor protein in the supernatant
fraction (SN) after solubilization and ultracentrifugation. Because
heavily aggregated receptors would not be amenable to solubili-
zation with mild detergents such as DDM and CHAPS used in this
study, the presence of detergent-solubilized misfolded NTS1
would indicate only minor receptor defects compromising agonist
binding. To investigate this hypothesis, we performed [
3H]NT
saturation binding analyses to determine the amount of functional
NTS1 in E. coli cells and in the SN fraction. We then compared
these data to those obtained from Western blots and ImageJ
analyses to estimate the total amount of NTS1 protein in E. coli
cells and in the SN using purified NTS1 fusion protein for the
standard curve. We found that the amount of NTS1 determined
by [
3H]NT saturation binding (i.e. functional receptors) was
greater (.130%, data not shown) than that determined by
Western blot analysis (total NTS1 protein), suggesting that NTS1
is ‘‘more than 100% functional’’ in E. coli cells and in the SN. One
explanation for this observation would be incomplete transfer of
NTS1 from the SDS-gels onto polyvinylidene fluoride membranes
resulting in an underestimate of the total receptor protein. Indeed,
we observed by silver staining residual NTS1 protein in gels after
the Western blot procedure using purified NTS1 protein for test
purposes (data not shown). Although we cannot conclude whether
some misfolded NTS1 protein originated during expression in E.
coli cells, and if so to what extent, our data do not indicate the
presence of large amounts of misfolded receptors in E. coli cells or
SN.
Because the NiE, NTFT and NTE fractions were enriched in
NTS1 and contained only a limited number of contaminants
(Figure 1), receptors were directly visualized on SDS-gels after
Coomassie-staining eliminating the need of Western blotting for
NTS1 identification. The quantification of total NTS1 protein was
achieved by ImageJ analysis of SDS-gels comparing the intensities
of Coomassie-stained receptors with those of defined amounts of
purified NTS1 standards (Table 4). The amount of functional
receptors was estimated by [
3H]NT saturation binding (Tables 3
and 4). We found that 80% of NTS1 in the NiE was functional.
The NTFT contained misfolded receptor, and the NTE consisted
of pure fully functional NTS1 (Table 4).
Misfolded NTS1 may arise during purification when correctly
folded receptors suffer damage by exposure to detergents and/or
to potentially destabilizing buffer compositions; these effects would
Table 4. Percentage of functional NTS1.
Total protein by Amido Black (mg) Total NTS1 protein (mg) Functional NTS1 (mg) Percent functional
NiE loaded 0.9260.06 0.44360.036 (6 gels) 0.355 80%
NTFT 0.5360.03 0.17160.007 (4 gels) 0.007 4%
NTE 0.1360.01 0.12360.009 (3 gels) 0.124 101%
The total protein content of the NiE, NTFT and NiE fractions was determined by the Amido Black method (Table 3). The amount of total NTS1 in the NiE, NTFT and NiE
fractions was determined by ImageJ analysis of Coomassie-stained gels. The number of functional NTS1 in pmoles (Table 3) was converted into a milligram value using
an NTS1 molecular mass of 96.5 kDa. The percent functionality was calculated as [(mg NTS1 by ligand binding analysis)/(mg NTS1 by SDS-PAGE analysis)]*100.
doi:10.1371/journal.pone.0012579.t004
Figure 1. Purification of NTS1. The progress of purification was
monitored by SDS-PAGE (NuPAGE 4–12% Bis-Tris gel, Invitrogen, 16
MES SDS buffer) and SimplyBlue staining. Lane M: Novagen Perfect
Protein Marker (15–150 kDa); lanes SN, NiE and NTFT: 5 mg of protein
per lane; lane NTE: 3 mg of protein. Abbreviations are as in Table 3.
doi:10.1371/journal.pone.0012579.g001
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this possibility, we determined the stability of NTS1 in SN, NiE
and diluted NiE (Table 1). Receptors in these fractions are exposed
to different concentrations of detergent, lipid and salt in the
absence of NT, and we observed a decrease in the amount of
functional NTS1 over time. The stability of NTS1 was
comparable in the SN and NiE fractions indicating that changes
in detergent concentration (DDM 1%R0.1%; the CHAPS and
CHS concentrations change much less) and possibly in lipid
content had no profound effect on the receptor half-lives at these
purification stages. However, lowering the NaCl and imidazole
concentrations from 200 mM (NiE) to 70 mM (diluted NiE)
reduced the half-life of NTS1 by about 3-fold. The concomitant
change in receptor concentration was 2.85-fold (see Materials and
Methods) and hence is less likely to explain the reduced NTS1
stability in the diluted NiE fraction compared to NiE. The
solubilization and IMAC step required 24 hours for completion,
while the NT column step was completed after 6 hours. During
these time intervals, less than 10% of receptor functionality was
lost at each step (Table 1). Although small, we accounted in
Table 2 for the amount of misfolded NTS1 generated by exposure
to detergent and various buffer compositions.
Table 2 shows the estimates of functional NTS1, misfolded
NTS1, contaminants and total protein in the NiE, NTFT and
NTE fractions. We used three different ways (see columns A–C in
Table 2) to describe those parameters; we realize some
interdependence because of overlapping use of data from radio-
ligand binding assays and from Amido Black protein determina-
tion. Column A shows the amounts of functional NTS1; for NiE,
this was corrected for receptor instability in buffer with low NaCl
content over the time period needed for completion of the NT
column step (Table 1). Column B lists information from ImageJ
analyses of SDS-gels which gives an estimate of the total amount of
NTS1 by comparing the Coomassie Blue intensities of NTS1
bands in the respective purification fractions to a standard curve
with purified receptor. By considering radio-ligand binding data,
the amount of misfolded NTS1 was calculated in each fraction.
The amount of contaminants was determined as the difference
between the total protein content of a purification fraction and the
respective total NTS1 protein. Column C uses the specific [
3H]NT
binding values of the NiE and NTE fractions, calculated from
[
3H]NT binding and from the protein content by the Amido Black
method (Table 3), to determine the amount of functional NTS1.
The average estimates of functional NTS1, misfolded NTS1,
contaminants and total protein in the NiE, NTFT and NTE
fractions are listed in column D of Table 2. In the NiE fraction,
,25% of the total NTS1 protein or 0.12 mg was misfolded. In
contrast, the NTFT and NTE fractions contained 0.17 mg of
misfolded NTS1, an increase to 143% (Tables 2 and 5). This was
surprising because on average we could not account for ,30% of
the total protein, contaminants and NTS1 protein in the NTFT
and NTE fractions compared to the NiE load (Table 5). Hence
this increase of misfolded NTS1 rather than the expected decrease
by ,30% indicated that misfolded NTS1 was generated during
the NT column step. To investigate whether NTS1 assumed an
aggregation-prone conformation by virtue of binding its agonist,
we performed stability measurements of NTS1 in buffer NT70 in
the presence or absence of NT. NTS1 was considerably more
stable with ligand bound (Figure 2) suggesting that the event of
agonist binding per se on the NT column was unlikely to contribute
Figure 2. Stability of NTS1 in NT70 buffer with and without
agonist. Receptors were incubated with [
3H]NT (open squares) or kept
in NT70 buffer without agonist (filled squares) at 4uC. [
3H]NT binding
was determined at the indicated time points. The data shown are from
2 independent experiments.
doi:10.1371/journal.pone.0012579.g002
Table 5. Summary of NTS1 purification.
Protein (mg) Protein (percent) Unaccounted (mg) Unaccounted (percent)
NiE
Functional NTS1 0.312 100
Misfolded NTS1 0.119 100
Total NTS1 0.443 100
Contaminants 0.477 100
Total protein 0.920 100
NTFT+NTE
Functional NTS1 0.131 42 20.181 58
Misfolded NTS1 0.170 143 +0.051 (43)
Total NTS1 0.297 67 20.146 33
Contaminants 0.366 77 20.111 23
Total protein 0.657 71 20.263 29
The percent values refer to the respective protein species in the NiE.
doi:10.1371/journal.pone.0012579.t005
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close proximity of the receptor to the NT column resin may lead to
receptor destabilization.
Discussion
Previously, we reported a robust two-step purification procedure
for NTS1 using IMAC followed by a NT column step [8]. Whilst
the NT column eluate contained functional receptor protein, the
NT column flow-through contained misfolded NTS1. Our data
presented here point towards two ways by which misfolded NTS1
may be generated.
First, correctly folded NTS1 suffers damage by exposure to
detergent and by changes in buffer composition as seen by the loss
of [
3H]NT binding over time in the SN, NiE and diluted NiE
fractions (Figure 2, Table 1). For the Ni-NTA column step, 86% of
[
3H]NT binding sites can be found in the combined NiFT (13%)
and NiE (73%) fractions when compared to the SN (Table 3).
Because the amount of functional NTS1 in the SN fraction is
reduced by 9% over the 24 hour time period needed for
completion of solubilization and the IMAC step (Table 1), almost
all [
3H]NT binding sites are accounted for, suggesting that
immobilization per se of NTS1 via the C-terminal histidine tag does
not result in substantial receptor destabilization.
Second, the NT column step generates additional receptor
protein which is misfolded, thereby reducing the yield of pure,
functional NTS1. The use of a NT column is required to efficiently
remove contaminants contained in the eluate of the Ni-NTA
column. The following four points may contribute to the instability
of NTS1 during the NT column step:
(A) Binding of NT to NTS1 may cause an NTS1 conformation
which is structurally unstable: Exposure of purified NTS1 to
agonist allows the receptor to assume a conformation
capable of catalyzing nucleotide exchange at Gaqb1c2 in
detergent solution [9]. Currently it is unknown whether the
conformation of agonist-loaded NTS1 in the absence of G-
protein is the same or is different from the conformation of
NTS1 in complex with NT and G-protein (see [15]), and
hence we cannot comment on the biochemical properties of
such specified NTS1 states. However, NT binding per se is
unlikely to trigger misfolding of NTS1 on the NT column
because agonist-loaded NTS1 is more stable than unoccu-
pied NTS1 in NT70 buffer (Figure 2). Similar observations
were made with NTS1 directly after solubilization [16] and
with structurally unstable constitutively active receptor
mutants that could be stabilized by agonist addition [17–
19].
(B) Close proximity of NTS1 to the NT column matrix may
destabilize NTS1: NT is attached to the NT column matrix
via an N-terminal biotin group bound to immobilized
tetrameric avidin [6]. The NT binding site of NTS1 has
been mapped by mutagenesis experiments and modeling
studies to residues in TM6, TM7 and the extracellular loop
3 [20–22]. We speculate that binding of NTS1 to the NT
column therefore brings the receptor into close contact with
avidin and the Sepharose matrix possibly causing pertur-
bations in the detergent belt surrounding the NTS1
transmembrane core leading to subsequent denaturation.
However, binding to Ni-NTA resin of the distant C-
terminal histidine tag, which is separated from the NTS1
tramsmembrane core by the NTS1 C-terminus of ,40
amino acid residues and the E. coli thioredoxin spacer does
not cause appreciable receptor denaturation (see above).
(C) Aggregation of NTS1 on the NT column may result from a
high local receptor concentration: The NT column has a
theoretical ligand density of 100–120 mM [6]. If NTS1
binds to immobilized NT ligands as they become available
during the loading process from the top to the bottom of the
column, NTS1 would concentrate locally to ,12 mg/ml
(120 mM, molecular mass of 96.5 kDa for the NTS1 fusion
protein). In contrast, the concentration of NTS1 bound to
Ni-NTA resin would be lower because of the reduced
apparent capacity of the IMAC column (,0.5 mg receptor
fusion protein / ml resin or 5 mM; see references [8,23]).
The concentrations of NTS1 in the SN, NiE and NTE
fractions range from 0.13–0.37 mM, respectively (Table 3),
and the receptor stability test in the diluted NiE fraction
(Figure 2) was done at an NTS1 concentration of only 9–
10 nM. Hence, the use of the NT column constitutes a step
in the presented purification scheme at which NTS1 may
concentrate to a threshold initiating receptor denaturation.
However, use of a NT column with a theoretical ligand
density of 20 mM rather than 100–120 mM gave similar
results (data not shown) suggesting that local high NTS1
concentrations were unlikely to cause receptor aggregation.
(D) The observed destabilization may reflect properties specific
to NTS1: In contrast to NTS1, purification of an adenosine
A2a receptor fusion protein by antagonist xanthine amine
congener affinity chromatography with an estimated resin
capacity of 14 mM did not lead to substantial amounts of
A2a receptor protein in the antagonist column flow-through
[23]. This may reflect the fact that the A2a receptor is
inherently more stable than NTS1 [16,24].
Several recombinant G-protein-coupled receptors have been
purified for biochemical and structural work at large scale by
affinity tag chromatography, followed in some cases by receptor-
specific ligand columns. Examples are a Flag epitope at the
receptor N-terminus for use with an M1 antibody column [25–27],
or a poly-histidine tail at the receptor C-terminus for immobilized
metal affinity chromatography [7,8,23,25,28–34]. A 1D4 antibody
column [35,36] recognizing the extreme C-terminus of bovine
rhodopsin has been used for the single-step purification of
rhodopsin [37,38] and of a b-adrenergic receptor with the 1D4
epitope tag fused to its C-terminus [39]. Ligand-specific
purification steps have been reported for the b1- and b2-adrenergic
receptors (antagonist alprenolol column) [25–27,32,33], the A2a
receptor (antagonist xanthine amine congener column) [23], a
receptor for pituitary adenylate cyclase-activating polypeptide
(biotinylated PACAP38) [40], and NTS1 (agonist neurotensin
column) [8]. A destabilizing effect by the use of a receptor-specific
ligand column has not been reported in literature; such an effect,
as seen for NTS1, would certainly depend on a number of
variables such as the intrinsic stability of the GPCR, the exact
buffer and detergent conditions used during solubilization and
purification, and measures taken to increase receptor stability (see
[41]). Remarkably, a mutant b2-adrenergic receptor [28] and the
A2a receptor [30] have been purified to homogeneity by the sole
use of histidine tag chromatography steps; and the crystal
structures have subsequently been determined. A similar purifica-
tion approach is currently being evaluated for NTS1 to maximize
receptor yields.
Acknowledgments
DNA sequence analysis was done by the NINDS DNA Sequencing
Facility. N-terminal protein sequence analysis was performed by the
NINDS Protein/Peptide Sequencing Facility. Mass spectrometry was done
Stability of NTS1
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12579by the NIDDK Proteomics & Mass Spectrometry Core Facility. We thank
the Center for Biologics Evaluation and Research (Food and Drug
Administration, Bethesda, MD, USA) for the synthesis of biotinylated
neurotensin.
Author Contributions
Conceived and designed the experiments: JFW RG. Performed the
experiments: JFW. Analyzed the data: JFW RG. Wrote the paper: JFW
RG.
References
1. Gether U, Kobilka BK (1998) G Protein-coupled receptors II. Mechanism of
agonist activation. J Biol Chem 273: 17979–17982.
2. Ji TH, Grossmann M, Ji I (1998) G protein-coupled receptors I. Diversity of
receptor-ligand interactions. J Biol Chem 273: 17299–17302.
3. Tanaka K, Masu M, Nakanishi S (1990) Structure and functional expression of
the cloned rat neurotensin receptor. Neuron 4: 847–854.
4. Grisshammer R, Tate CG (1995) Overexpression of integral membrane proteins
for structural studies. Q Rev Biophys 28: 315–422.
5. Grisshammer R, Duckworth R, Henderson R (1993) Expression of a rat
neurotensin receptor in Escherichia coli. Biochem J 295: 571–576.
6. Tucker J, Grisshammer R (1996) Purification of a rat neurotensin receptor
expressed in Escherichia coli. Biochem J 317: 891–899.
7. Grisshammer R, Tucker J (1997) Quantitative evaluation of neurotensin
receptor purification by immobilized metal affinity chromatography. Protein
Expression and Purification 11: 53–60.
8. White JF, Trinh LB, Shiloach J, Grisshammer R (2004) Automated large-scale
purification of a G protein-coupled receptor for neurotensin. FEBS Lett 564:
289–293.
9. White JF, Grodnitzky J, Louis JM, Trinh LB, Shiloach J, et al. (2007)
Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters
G protein interaction. Proc Natl Acad Sci USA 104: 12199–12204.
10. Grisshammer R, Averbeck P, Sohal AK (1999) Improved purification of a rat
neurotensin receptor expressed in Escherichia coli. Biochemical Society Transac-
tions 27: 899–903.
11. Martin S, Botto J-M, Vincent J-P, Mazella J (1999) Pivotal role of an aspartate
residue in sodium sensitivity and coupling to G proteins of neurotensin receptors.
Mol Pharmacol 55: 210–215.
12. White JF, Grisshammer R (2007) Automated Large-Scale Purification of a
Recombinant G-Protein-Coupled Neurotensin Receptor. Current Protocols in
Protein Science: John Wiley & Sons, Inc. pp 6.8.1–6.8.31.
13. Schaffner W, Weissmann C (1973) A rapid, sensitive, and specific method for the
determination of protein in dilute solution. Anal Biochem 56: 502–514.
14. Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with ImageJ.
Biophotonics International 11: 36–42.
15. Yao XJ, Velez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, et al. (2009)
The effect of ligand efficacy on the formation and stability of a GPCR-G protein
complex. Proc Natl Acad Sci USA 106: 9501–9506.
16. Shibata Y, White JF, Serrano-Vega MJ, Magnani F, Aloia AL, et al. (2009)
Thermostabilization of the neurotensin receptor NTS1. J Mol Biol 390:
262–277.
17. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, et al. (2000)
The effect of mutations in the DRY motif on the constitutive activity and
structural instability of the histamine H(2) receptor. Mol Pharmacol 57:
890–898.
18. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, et al. (1997)
Structural instability of a constitutively active G protein-coupled receptor.
Agonist-independent activation due to conformational flexibility. J Biol Chem
272: 2587–2590.
19. Wilson MH, Limbird LE (2000) Mechanisms regulating the cell surface
residence time of the alpha 2A-adrenergic receptor. Biochemistry 39: 693–700.
20. Barroso S, Richard F, Nicolas-Ethe `ve D, Reversat JL, Bernassau JM, et al.
(2000) Identification of residues involved in neurotensin binding and modeling of
the agonist binding site in neurotensin receptor 1. J Biol Chem 275: 328–336.
21. Kitabgi P (2006) Functional domains of the subtype 1 neurotensin receptor
(NTS1). Peptides 27: 2461–2468.
22. Pang YP, Cusack B, Groshan K, Richelson E (1996) Proposed ligand binding
site of the transmembrane receptor for neurotensin(8–13). J Biol Chem 271:
15060–15068.
23. Weiß HM, Grisshammer R (2002) Purification and characterization of the
human adenosine A2a receptor functionally expressed in Escherichia coli.
Eur J Biochem 269: 82–92.
24. Magnani F, Shibata Y, Serrano-Vega MJ, Tate CG (2008) Co-evolving stability
and conformational homogeneity of the human adenosine A2a receptor. Proc
Natl Acad Sci USA 105: 10744–10749.
25. Kobilka BK (1995) Amino and carboxyl terminal modifications to facilitate the
production and purification of a G protein-coupled receptor. Anal Biochem 231:
269–271.
26. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. (2007)
Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.
Nature 450: 383–387.
27. Rosenbaum DM, Rasmussen SG, Kobilka BK (2009) The structure and
function of G-protein-coupled receptors. Nature 459: 356–363.
28. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, et al. (2008) A
specific cholesterol binding site is established by the 2.8 A structure of the human
beta2-adrenergic receptor. Structure 16: 897–905.
29. Hulme EC, Curtis CAM (1998) Purification of recombinant M1 muscarinic
acetylcholine receptor. Biochem Soc Trans 26: S361.
30. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, et al. (2008) The
2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an
antagonist. Science 322: 1211–1217.
31. Klaassen CH, Bovee-Geurts PH, Decaluwe GL, DeGrip WJ (1999) Large-scale
production and purification of functional recombinant bovine rhodopsin with
the use of the baculovirus expression system. Biochem J 342: 293–300.
32. Warne T, Chirnside J, Schertler GF (2003) Expression and purification of
truncated, non-glycosylated turkey beta-adrenergic receptors for crystallization.
Biochim Biophys Acta 1610: 133–140.
33. Warne T, Serrano-Vega MJ, Tate CG, Schertler GF (2009) Development and
crystallization of a minimal thermostabilised G protein-coupled receptor. Protein
Expr Purif 65: 204–213.
34. Yeliseev AA, Wong KK, Soubias O, Gawrisch K (2005) Expression of human
peripheral cannabinoid receptor for structural studies. Protein Science 14:
2638–2653.
35. Molday RS, MacKenzie D (1983) Monoclonal antibodies to rhodopsin:
characterization, cross-reactivity, and application as structural probes. Biochem-
istry 22: 653–660.
36. Oprian DD, Molday RS, Kaufman RJ, Khorana HG (1987) Expression of a
synthetic bovine rhodopsin gene in monkey kidney cells. Proc Natl Acad Sci
USA 84: 8874–8878.
37. Reeves PJ, Kim JM, Khorana HG (2002) Structure and function in rhodopsin: a
tetracycline-inducible system in stable mammalian cell lines for high-level
expression of opsin mutants. Proc Natl Acad Sci USA 99: 13413–13418.
38. Standfuss J, Xie G, Edwards PC, Burghammer M, Oprian DD, et al. (2007)
Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol 372:
1179–1188.
39. Chelikani P, Reeves PJ, Rajbhandary UL, Khorana HG (2006) The synthesis
and high-level expression of a beta2-adrenergic receptor gene in a tetracycline-
inducible stable mammalian cell line. Protein Science 15: 1433–1440.
40. Ohtaki T, Ogi K, Masuda Y, Mitsuoka K, Fujiyoshi Y, et al. (1998) Expression,
purification, and reconstitution of receptor for pituitary adenylate cyclase-
activating polypeptide. large-scale purification of a functionally active G protein-
coupled receptor produced in Sf9 insect cells. J Biol Chem 273: 15464–15473.
41. Grisshammer R (2009) Purification of recombinant G-protein-coupled receptors.
Methods Enzymol 463: 631–645.
Stability of NTS1
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12579